Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:GPCR NASDAQ:KNSA NYSE:RCUS NASDAQ:SPRY On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGPCRStructure Therapeutics$41.19+0.2%$52.99$15.80▼$94.90$2.92B-1.311.02 million shs224,531 shsKNSAKiniksa Pharmaceuticals International$57.82+1.9%$46.57$24.85▼$58.20$4.42B0.17705,171 shs238,947 shsRCUSArcus Biosciences$25.24-3.1%$22.69$7.06▼$28.72$3.16B0.871.25 million shs585,672 shsSPRYARS Pharmaceuticals$9.33+3.3%$8.41$6.66▼$18.90$925.68M0.931.50 million shs567,328 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for May 2026. Learn which stocks have the most short interest and how to trade them. Click the link to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGPCRStructure Therapeutics-2.63%-5.65%-23.15%-49.42%+49.18%KNSAKiniksa Pharmaceuticals International+2.66%+5.37%+16.22%+30.38%+104.25%RCUSArcus Biosciences+1.40%+5.47%+13.44%+24.45%+192.17%SPRYARS Pharmaceuticals+5.49%+13.73%+8.80%-10.95%-36.68%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGPCRStructure Therapeutics$41.19+0.2%$52.99$15.80▼$94.90$2.92B-1.311.02 million shs224,531 shsKNSAKiniksa Pharmaceuticals International$57.82+1.9%$46.57$24.85▼$58.20$4.42B0.17705,171 shs238,947 shsRCUSArcus Biosciences$25.24-3.1%$22.69$7.06▼$28.72$3.16B0.871.25 million shs585,672 shsSPRYARS Pharmaceuticals$9.33+3.3%$8.41$6.66▼$18.90$925.68M0.931.50 million shs567,328 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for May 2026. Learn which stocks have the most short interest and how to trade them. Click the link to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGPCRStructure Therapeutics-2.63%-5.65%-23.15%-49.42%+49.18%KNSAKiniksa Pharmaceuticals International+2.66%+5.37%+16.22%+30.38%+104.25%RCUSArcus Biosciences+1.40%+5.47%+13.44%+24.45%+192.17%SPRYARS Pharmaceuticals+5.49%+13.73%+8.80%-10.95%-36.68%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGPCRStructure Therapeutics 2.89Moderate Buy$109.25164.46% UpsideKNSAKiniksa Pharmaceuticals International 2.67Moderate Buy$60.866.03% UpsideRCUSArcus Biosciences 2.64Moderate Buy$32.4427.86% UpsideSPRYARS Pharmaceuticals 2.40Hold$28.25204.78% UpsideCurrent Analyst Ratings BreakdownLatest SPRY, KNSA, GPCR, and RCUS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/4/2026RCUSArcus Biosciences Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy4/29/2026KNSAKiniksa Pharmaceuticals International Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$62.00 ➝ $64.004/29/2026KNSAKiniksa Pharmaceuticals International CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$50.00 ➝ $60.004/29/2026KNSAKiniksa Pharmaceuticals International WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$58.00 ➝ $59.004/29/2026KNSAKiniksa Pharmaceuticals International Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$53.00 ➝ $57.004/28/2026KNSAKiniksa Pharmaceuticals International Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$58.00 ➝ $71.004/27/2026GPCRStructure Therapeutics Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$101.004/27/2026GPCRStructure Therapeutics Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy$101.004/24/2026SPRYARS Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D) ➝ Sell (D-)4/21/2026GPCRStructure Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/21/2026KNSAKiniksa Pharmaceuticals International Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C)(Data available from 5/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGPCRStructure TherapeuticsN/AN/AN/AN/A$24.99 per shareN/AKNSAKiniksa Pharmaceuticals International$677.56M6.48$0.79 per share72.59$7.91 per share7.26RCUSArcus Biosciences$247M12.91N/AN/A$5.84 per share4.35SPRYARS Pharmaceuticals$84.28M10.92N/AN/A$1.16 per share7.99Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGPCRStructure Therapeutics-$141.20M-$0.79N/AN/AN/AN/A-25.90%-24.54%5/7/2026 (Estimated)KNSAKiniksa Pharmaceuticals International$59.01M$0.9063.7035.43N/A9.69%13.26%9.86%N/ARCUSArcus Biosciences-$353M-$3.30N/AN/AN/A-142.91%-65.77%-32.51%N/ASPRYARS Pharmaceuticals-$171.30M-$1.75N/AN/AN/A-203.25%-100.29%-51.09%5/13/2026 (Estimated)Latest SPRY, KNSA, GPCR, and RCUS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2026Q1 2026SPRYARS Pharmaceuticals-$0.50N/AN/AN/A$22.31 millionN/A5/7/2026Q1 2026GPCRStructure Therapeutics-$0.39N/AN/AN/A$10.00 millionN/A5/5/2026Q1 2026RCUSArcus Biosciences-$0.92-$1.02-$0.10-$1.02$29.49 million$17.00 million4/28/2026Q1 2026KNSAKiniksa Pharmaceuticals International$0.18$0.27+$0.09$0.27$206.11 million$214.27 million3/9/2026Q4 2025SPRYARS Pharmaceuticals-$0.42-$0.42N/A-$0.42$25.58 million$28.09 million2/26/2026Q4 2025GPCRStructure Therapeutics-$0.35-$0.49-$0.14$999.00$7.14 millionN/A2/25/2026Q4 2025RCUSArcus Biosciences-$1.11-$0.89+$0.22-$0.89$24.94 million$33.00 million2/24/2026Q4 2025KNSAKiniksa Pharmaceuticals International$0.29$0.17-$0.12$0.17$200.86 million$202.13 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthGPCRStructure TherapeuticsN/AN/AN/AN/AN/AKNSAKiniksa Pharmaceuticals InternationalN/AN/AN/AN/AN/ARCUSArcus BiosciencesN/AN/AN/AN/AN/ASPRYARS PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGPCRStructure TherapeuticsN/A24.8124.81KNSAKiniksa Pharmaceuticals InternationalN/A3.793.33RCUSArcus Biosciences0.164.364.36SPRYARS Pharmaceuticals1.477.287.06Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGPCRStructure Therapeutics91.78%KNSAKiniksa Pharmaceuticals International53.95%RCUSArcus Biosciences92.89%SPRYARS Pharmaceuticals68.16%Insider OwnershipCompanyInsider OwnershipGPCRStructure Therapeutics5.60%KNSAKiniksa Pharmaceuticals International53.48%RCUSArcus Biosciences9.60%SPRYARS Pharmaceuticals33.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGPCRStructure Therapeutics13670.84 million66.88 millionOptionableKNSAKiniksa Pharmaceuticals International22076.54 million35.60 millionOptionableRCUSArcus Biosciences500125.63 million113.57 millionOptionableSPRYARS Pharmaceuticals9099.30 million66.04 millionOptionableSPRY, KNSA, GPCR, and RCUS HeadlinesRecent News About These CompaniesEarnings Preview: ARS Pharmaceuticals, Inc. (SPRY) Q1 Earnings Expected to Decline1 hour ago | zacks.comARS Pharmaceuticals (SPRY) Projected to Post Quarterly Earnings on Wednesday3 hours ago | marketbeat.comARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Given Consensus Rating of "Hold" by BrokeragesMay 4 at 6:22 AM | marketbeat.comHow The ARS Pharmaceuticals (SPRY) Narrative Is Shifting With Fresh Analyst Models And ApprovalsMay 2, 2026 | finance.yahoo.comARS Pharmaceuticals, Inc. (SPRY) Soars 7.1%: Is Further Upside Left in the Stock?April 23, 2026 | zacks.comNorthland Highlights ARS Pharmaceuticals, Inc. (SPRY) Needle-Free Therapy as Major Innovation DriverApril 17, 2026 | insidermonkey.comHealth Canada Approves neffy Nasal Spray for Anaphylaxis Treatment in Canada, Available Summer 2026April 15, 2026 | quiverquant.comQneffy® (epinephrine nasal spray) Approved in Canada as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis)April 15, 2026 | globenewswire.comQ1 Earnings Forecast for SPRY Issued By Northland SecuritiesApril 13, 2026 | marketbeat.comARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Given Consensus Recommendation of "Hold" by AnalystsApril 9, 2026 | marketbeat.comARS Pharmaceuticals (NASDAQ:SPRY) Coverage Initiated by Analysts at Northland SecuritiesApril 9, 2026 | marketbeat.comARS Pharmaceuticals Receives FDA Approval to Remove Age Requirement From neffy® 1 mg (epinephrine nasal spray) LabelMarch 27, 2026 | globenewswire.comARS Pharmaceuticals Inc.March 21, 2026 | barrons.comARS Pharmaceuticals: Neffy's Slow Launch, No Guidance For 2026 Keep Me On SidelinesMarch 11, 2026 | seekingalpha.comARS Pharmaceuticals Inc (SPRY) Q4 2025 Earnings Call Highlights: Strong Market Entry and ...March 10, 2026 | finance.yahoo.comARS Pharmaceuticals, Inc. (SPRY) Q4 2025 Earnings Call TranscriptMarch 9, 2026 | seekingalpha.comARS Pharmaceuticals, Inc. (SPRY) Reports Q4 Loss, Beats Revenue EstimatesMarch 9, 2026 | zacks.comARS Pharmaceuticals, Inc.: ARS Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Updates on neffy (epinephrine nasal spray) CommercializationMarch 9, 2026 | finanznachrichten.deARS Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Updates on neffy® (epinephrine nasal spray) CommercializationMarch 9, 2026 | globenewswire.comWhat To Expect From ARS Pharmaceuticals Inc (SPRY) Q4 2025 EarningsMarch 7, 2026 | finance.yahoo.comExploring ARS Pharmaceuticals's Earnings ExpectationsMarch 6, 2026 | benzinga.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesWith Nike Shares Near a 12-Year Low, Is Now the Time to Be Brave?By Sam Quirke | April 12, 20263 Dividend Aristocrats Whose Yields Can Help Combat InflationBy Chris Markoch | April 9, 2026The War Won't Last Forever: 3 Stocks That Could Lead the RecoveryBy Bridget Bennett | April 8, 20263 Discounted Stocks With Strong Rebound PotentialBy Chris Markoch | April 6, 20263 Ways to Invest in the Growing GLP-1 Weight Loss MarketBy Nathan Reiff | April 17, 2026SPRY, KNSA, GPCR, and RCUS Company DescriptionsStructure Therapeutics NASDAQ:GPCR$41.18 +0.09 (+0.21%) As of 12:02 PM Eastern This is a fair market value price provided by Massive. Learn more.Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. It is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist for apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF); and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF and PPF. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.Kiniksa Pharmaceuticals International NASDAQ:KNSA$57.82 +1.08 (+1.91%) As of 12:02 PM Eastern This is a fair market value price provided by Massive. Learn more.Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. The company was incorporated in 2015 and is based in Hamilton, Bermuda.Arcus Biosciences NYSE:RCUS$25.24 -0.82 (-3.15%) As of 12:02 PM Eastern This is a fair market value price provided by Massive. Learn more.Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies. It also develops Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in Phase 2 clinical trial; Quemliclustat, a small-molecule CD73 inhibitor, which is Phase 1b and Phase 2 clinical trial; Zimberelimab, an anti-PD-1 antibody, which is in Phase 2 clinical trial for metastatic cell lung cancer and monotherapy; and AB521, an oral and small-molecule inhibitor of HIF-2a, which is in Phase 1 clinical trial for the treatment of Von Hippel-Lindau disease. In addition, the company's preclinical pipeline products include AB598, a CD39 antibody; and AB801, a small molecule Axl inhibitor. It has a clinical collaboration with AstraZeneca to evaluate domvanalimab in combination with durvalumab in a registrational phase 3 clinical trial in patients with unresectable Stage 3 NSCLC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is headquartered in Hayward, California.ARS Pharmaceuticals NASDAQ:SPRY$9.32 +0.30 (+3.27%) As of 12:02 PM Eastern This is a fair market value price provided by Massive. Learn more.ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Just How Big a Problem Could Amazon’s Cash Burn Rate Be? BlackBerry Rewrites Its Own Operating System Grab Holdings Faces Hurdles, But Upside Potential Is Hard to Ignore Palantir Drops After a Blowout Q1—What Investors Should Know Shopify’s Valuation Crisis Creates Opportunity in 2026 onsemi Stock Dips After Earnings: Why the Dip Is Buyable TSLA: 3 Reasons the Stock Could Hit $400 in May Nebius Breaks Out to All-Time Highs—Here's What's Driving It. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
